Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.

Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.

Relative effect of therapies indicated for the treatment of advanced renal cell carcinoma (aRCC) after failure of first line treatment is currently not known. The objective of the present study is to evaluate progression-free survival (PFS) and overall survival (OS) of cabozantinib compared to evero...

Full description

Bibliographic Details
Main Authors:	Billy Amzal, Shuai Fu, Jie Meng, Johanna Lister, Helene Karcher
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5590935?pdf=render

Similar Items

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
by: Meng J, et al.
Published: (2018-04-01)

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation
by: Steve J Edwards, et al.
Published: (2018-01-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
by: Kung-Hao Liang, et al.
Published: (2021-10-01)

Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report
by: Yueh-Shih Chang, et al.
Published: (2023-07-01)

Combination of everolimus with sorafenib for solid renal tumors in Tsc2+/- mice is duperior to everolimus alone
by: Yang, J, et al.
Published: (2017)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022-09-01)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
by: Lei Zhang, et al.
Published: (2020-09-01)

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
by: Brown, J, et al.
Published: (2024)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
by: Koichiro Takayama, et al.
Published: (2022-11-01)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
by: Romualdo Barroso-Sousa, et al.
Published: (2021-08-01)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
by: John Wright, et al.
Published: (2022-03-01)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
by: Haoyang Mi, et al.
Published: (2022-05-01)

Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab
by: Carlos Eduardo Salazar-Mejía, et al.
Published: (2020-12-01)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
by: Eva Juengel, et al.
Published: (2021-11-01)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
by: Ethan Emberley, et al.
Published: (2021-01-01)

Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)
by: Toni Choueiri
Published: (2015-11-01)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
by: Ethan Emberley, et al.
Published: (2021-01-01)

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
by: Incheon Kang, et al.
Published: (2021-10-01)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
by: Giandomenico Roviello, et al.
Published: (2022-08-01)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
by: Wen Cai, et al.
Published: (2019-10-01)

Overall survival and second primary malignancies in men with metastatic prostate cancer.
by: Juha Mehtälä, et al.
Published: (2020-01-01)

A high throughput method for Monitoring of Sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS/MS in rat plasma
by: Er-Min Gu, et al.
Published: (2022-09-01)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
by: Andrea S. Fung, et al.
Published: (2020-07-01)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
by: Shuming Zhang, et al.
Published: (2023-09-01)

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
by: Hwi Young Kim, et al.
Published: (2018-03-01)

Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
by: Osman Öcal, et al.
Published: (2022-01-01)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
by: Mariaelena Capone, et al.
Published: (2018-07-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
by: Rashad Ismayilov, et al.
Published: (2022-02-01)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
by: Thomas Powles, et al.
Published: (2021-08-01)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
by: Michikata Hayashida, et al.
Published: (2023-11-01)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
by: Caroline S. Jansen, et al.
Published: (2023-10-01)

A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study
by: Valentina D. A. Corino, et al.
Published: (2021-05-01)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
by: Chris Coppin
Published: (2010-04-01)

Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
by: Maurizio Biselli, et al.
Published: (2024-03-01)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
by: Thomas Powles, et al.
Published: (2021-09-01)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
by: Minas P. Economides, et al.
Published: (2020-11-01)

Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
by: Felix Peisen, et al.
Published: (2024-01-01)